SCHEMBL30980799

SCHEMBL30980799

NCCCOCC(COCCCN)(COCCCN)NC(=O)OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
ITGB3 P05106 4/20 0.45
ITGA2B P08514 4/20 0.45
CA12 O43570 2/20 0.45
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
CA9 Q16790 2/20 0.45
HTT P42858 1/20 0.44
TLR2 O60603 2/20 0.43
TSHR P16473 1/20 0.42
CASP1 P29466 1/20 0.42
CTSS P25774 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19767522 0.87 SMN1; SMN2 (0.49) LMNASMN1; SMN2MEN1KMT2ACA12
SCHEMBL10177562 0.86 HTT (0.48) LMNASMN1; SMN2ITGB3ITGA2BHTT
SCHEMBL5057001 0.84 HTT (0.52) LMNASMN1; SMN2MEN1KMT2ACA12
SCHEMBL30980519 0.83 MEN1 (0.49) LMNASMN1; SMN2MEN1KMT2AITGB3
SCHEMBL20970466 0.83 HTT (0.50) LMNASMN1; SMN2MEN1KMT2AHTT
SCHEMBL16248649 0.82 SMN1; SMN2 (0.49) LMNASMN1; SMN2MEN1KMT2ACA12
SCHEMBL24052423 0.81 HTT (0.46) LMNASMN1; SMN2ITGB3ITGA2BHTT
SCHEMBL9604578 0.81 MEN1 (0.52) LMNASMN1; SMN2MEN1KMT2ACA12
SCHEMBL12108556 0.81 CTSS (0.48) LMNASMN1; SMN2MEN1KMT2ACA12
SCHEMBL6564258 0.81 MEN1 (0.50) LMNASMN1; SMN2MEN1KMT2ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651904-A1 LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF AUTOANTIBODIES Lycia Therapeutics, Inc. (US) 2025-11-26 EP disclosed
EP-4651901-A1 CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 EP disclosed
EP-4651902-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 EP disclosed
WO-2025035040-A1 LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES LYCIA THERAPEUTICS, INC. (US) 2025-02-13 WO disclosed
WO-2024155747-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. (US) 2024-07-25 WO disclosed
WO-2024155750-A1 LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF AUTOANTIBODIES LYCIA THERAPEUTICS, INC. (US) 2024-07-25 WO disclosed